Litevax adjuvant

1 paper5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: European Commission and 1 more

Human trial1

Outcomes

Age-related differences in early immune responses

downin humans1

1 study

Litevax adjuvant decreases age-related differences in early immune responses in humans.
“LVA reduced age-related differences in early immune responses”
Human trialreceiving a quadrivalent influenza vaccine
LiteVax-adjuvanted influenza vaccine induces transient interferon-driven innate activation and accelerates early IgG3 responses in older adults
Research Square3 Aug 2026Preprint

Overall antibody magnitude

no changein humans1

1 study

Litevax adjuvant has no effect on overall antibody magnitude in humans.
“without affecting overall antibody magnitude”
Human trialreceiving a quadrivalent influenza vaccine
LiteVax-adjuvanted influenza vaccine induces transient interferon-driven innate activation and accelerates early IgG3 responses in older adults
Research Square3 Aug 2026Preprint

Latest

1 in 12 months

Research Square4 Aug